Clinical Research Directory

Inclusion Criteria: * Patients with a confirmed diagnosis of dilated cardiomyopathy under the supervision of a physician or a heart failure nurse specialist. * NYHA class ≥ 2 symptoms despite having received optimal medical therapy and appropriate device therapy, as per clinical guidelines for an interval of at least 3 months. * No other treatment options available as part of the current best standard of care. * LVEF ≤35% on any imaging modality performed as part of the screening phase. Exclusion Criteria: * Congenital heart disease. * Clinically significant valvular heart disease. * Patients who are not suitable for a Percutaneous Mechanical Support Device (E.g. unsuitable femoral artery anatomy, unable able to lie flat for prolonged time to accommodate the stem cell infusion \& presence of LV thrombus) * Weight of patient that exceeds the maximum limit of the cardiac catheterisation laboratory table / CT scanner. * Cardiomyopathy 2o to a reversible cause that has not been treated e.g. thyroid disease, alcohol abuse, hypophosphataemia, hypocalcaemia, cocaine abuse, selenium toxicity \& chronic uncontrolled tachycardia. * Cardiomyopathy in association with a neuromuscular disorder e.g. Duchenne's progressive muscular dystrophy. * Previous cardiac surgery. * Contra-indication for bone marrow aspiration (thrombocytopaenia - platelet count \<80 x 10(9)/L or extensive surgical scarring/anatomical deformity at site of bone marrow puncture). * Known active infection on admission as defined by a temperature \>37.5°C or on a short course of antibiotics. * An active infection of hepatitis B, hepatitis C, syphilis or HTLV * Known HIV infection * Chronic inflammatory disease requiring on-going medication. * Concomitant disease with a life expectancy of less than one year * Follow-up impossible (no fixed abode, etc.) * Neoplastic disease without documented remission within the past 5 years. * Patients on renal replacement therapy. * Subjects of childbearing potential unless βHCG negative and are on adequate contraception during the trial. * Patients falling into the vulnerable category or lacking capacity * Patients who are unable to understand or read written English will be excluded from the trial. * Killip Class III or above